Changes in Cognition During a 24-h Simulated Military Operation

Cognitive Impairment Clinical Trial

Official title:

Changes in Cognition During a 24-h Simulated Military Operation (SUSOP). Influence of β-alanine Supplementation and Markers of Classical Monocyte Recruitment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04250480
• Other study ID #: SBE-17-13223
• Status: Completed
• Phase: N/A
• Start date: October 2, 2017
• Est. completion date: April 15, 2018

Study information

• Verified date: January 2020
• Source: University of Central Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sustained military operations (SUSOPs) result in psychological stress and cognitive dysfunction, which may be related to the recruitment of classical monocytes into the brain.

Goals:

• To investigate the effect of sustained-release beta-alanine on changes in cognition and markers of immune cell recruitment during a 24-hour simulated military operation.

• To examine associations between changes cognition and changes in markers mediating immune cell recruitment.

Description:

Sustained military operations (SUSOPs) expose soldiers to a multitude of stressors, including sustained physical activity, caloric deficit, and sleep deprivation. Several studies have shown that the combination of these factors result in psychological stress, which often leads to significant cognitive impairment.

Psychological stress has been shown to result in activation of neuroendocrine pathways that signal into the periphery and relay information from the brain to the immune system. This process is generally characterized by elevations of several key pro-inflammatory cytokines, chemokines, secondary messengers and reactive oxygen species. Notably, peripheral classical monocytes are reported to undergo recruitment to the brain during periods of psychological stress following priming by cytokines secreted from activated microglia.

Carnosine, an endogenous dipeptide consisting of beta-alanine and L-histidine, has been shown to inhibit the synthesis of inflammatory and oxidative mediators in microglia in vitro. Beta-alanine, which is the rate limiting amino acid in carnosine formation has been shown to increase carnosine concentrations in various regions of the brain in rodents which been associated with biochemical changes that resulted in favorable improvements in resilience to stress exposure. However, data on the effects of beta-alanine supplementation on cognition in humans is less clear. Further, the effect of beta-alanine supplementation on systemic and cellular mediators of monocyte recruitment has not been examined.

Goals:

• To investigate the effect of sustained-release beta-alanine on changes in psychological stress and cognition using Automated Neuropsychological Assessment Metric (ANAM) cognitive assessments during a 24-hour simulated military operation.

• To examine the effect of sustained-release beta-alanine on monocyte chemoattractant protein-1 (MCP-1), interleukin-8, Lymphocyte function-associated antigen-1 (CD11a), macrophage-1-antigen (CD11b) expression and C-C chemokine receptor 2 (CCR2) expression on neutrophils and classical monocytes during a 24-hour simulated military operation.

• To examine associations between MCP-1, interleukin-8, CD11a, CD11b, CCR2 and a composite measure of cognition derived from ANAM assessment scores during a 24-hour simulated military operation.

Method:

Double-blind placebo controlled trial compared the effect of supplementation with sustained release beta-alanine (12 grams per day) versus placebo (equivalent amount of rice powder) on cognition and monocyte responses during a 24-hour simulated military operation consisting of sleep-restriction, caloric restriction, and acute and sustained periods military specific physical activity.

Supplementation occurred over a period of 14 days prior to completion of the simulated military operation. ANAM tests were assessed and blood samples taken upon arrival to the lab for the 24 hour simulated operation (0 hours) and at 12, 18 and 24 hours during the SUSOP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 15, 2018
• Est. primary completion date: April 15, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Participants in this study will be males aged 18-35, preferably with military training or are current Reserve Officers' Training Corps cadets

• Free of any physical limitations (determined by medical and activity history questionnaire [MHQ] and the physical activity readiness questionnaire [PAR-Q+]).

• Participants will be required to be recreationally-active (defined according to American College of Sports Medicine standards of at least 150 minutes exercise per week).

• Participants must be willing abstain from dietary supplementation throughout the duration of the study.

• Participant understands the study procedures and signs forms providing informed consent to participate in the study.

Exclusion Criteria:

• Individual does not provide consent to participate in this study.

• Inability to perform physical exercise (determined by health and activity questionnaire [MHQ] and physical activity readiness questionnaire [PAR-Q+]). That is Answering "Yes" to any question on the PAR-Q+, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.

• Taking any other nutritional supplement or performance-enhancing drug (determined from health and activity questionnaire).

• Regularly taking any type of prescription or over-the-counter medication, or having any chronic illnesses, which require medical care.

• Inability to complete any of the exercise performance testing on the familiarization day.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Cognitive Impairment

Intervention

Dietary Supplement:
• beta-alanine
beta-alanine tablet
• placebo
rice powder tablet

Locations

Country	Name	City	State
United States	Kinesiology Research Labs	Orlando	Florida

Sponsors (2)

Lead Sponsor	Collaborator
University of Central Florida	National Strength and Conditioning Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptoms checklist	monitor frequency and severity of subjective symptoms related to a broad spectrum of conditions. The participant is presented with 21 symptoms. The participant is required to rate each symptom (e.g. fatigue, headache, Nausea, numbness/tingling etc. on a scale from 0 (Not Present) to 6 (Severe)	Change from 0 at 12, 18 and 24 hours
Primary	COGcomp (composite measure of cognition)	Throughput (TP) scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include: Simple reaction time; Code Substitution; Procedural Reaction Time; Mathematical processing; Matching to sample; Code substitution Delayed; Simple reaction time repeat	Change from 0 at 12, 18 and 24 hours
Primary	Monocyte chemoattractant protein-1 (MCP-1)	Serum concentrations of MCP-1	Change from 0 at 12, 18 and 24 hours
Primary	Macrophage-1-antigen (CD11b)	Surface expression of CD11b on classical monocytes and neutrophils	Change from 0 at 12, 18 and 24 hours
Primary	C-C chemokine receptor 2 (CCR2)	Surface expression of CCR2 on classical monocytes	Change from 0 at 12, 18 and 24 hours
Primary	Interleukin-8	Serum concentrations of interleukin-8	Change from 0 at 12, 18 and 24 hours
Primary	Lymphocyte function-associated antigen-1 (CD11a)	Surface expression of CD11a on classical monocytes and neutrophils	Change from 0 at 12, 18 and 24 hours